Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon.

Abstract

Calcitonin gene-related peptide (CGRP) is a potent vasodilator that may be involved in the regulation of the peripheral circulation and in its response to cold. There is evidence that CGRP in digital cutaneous perivascular nerves is deficient in Raynaud's phenomenon. Our pilot study of intravenous CGRP suggested that this substance is beneficial in patients with Raynaud's phenomenon; here we have extended our studies. Ten patients with severe Raynaud's phenomenon secondary to connective tissue disease were randomly assigned to groups receiving intravenous CGRP (0.6 micrograms/min for 3 h per day on 5 days) or saline. Hand and digital blood flow and skin temperature were measured by thermocouple and laser doppler flowmetry. Blood flow was significantly (p < 0.05) increased by CGRP in both hands (median blood flow after infusion as percentage of baseline reading 179 [range 100-355]%) and fingers (149 [100-161]%); saline had no effect (hands 102 [84-123]%, fingers 96 [81-113]%). Hand temperature was increased more by CGRP than by saline (2.8 [1.5-4.0] vs 1.0 [-1.0 to 2.5] degrees C, p < 0.05). Digital temperature increased after CGRP but the difference between the treatment groups in temperature rise was not significant, perhaps because saline caused increases in some patients. All ulcers healed in four of five CGRP-treated patients but in no saline-treated patients. Thus intravenous CGRP effectively dilates the compromised digital cutaneous vasculature in severe Raynaud's phenomenon.